Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
Earnings for Innate Pharma S.A. (IPHA)
Earnings in 2023 (TTM): $-7,570,000
According to Innate Pharma S.A.'s latest financial reports the company's current earnings (TTM) are $-7,570,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Innate Pharma S.A.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-7,570,000 | $-7,570,000 |
| 2022 | $-57,972,000 | $-99,103,000 |
| 2021 | $-45,478,000 | $-59,136,000 |
| 2020 | $-63,984,000 | $-70,747,000 |
| 2019 | $-20,759,000 | $-20,965,000 |
| 2018 | $2.72 M | $3.05 M |
| 2017 | $-48,016,000 | $-48,385,000 |
| 2016 | $12.94 M | $12.64 M |
| 2015 | $-6,706,000 | $-6,706,000 |
| 2014 | $-19,647,000 | $-19,647,000 |
| 2013 | $-2,892,000 | $-2,892,000 |
| 2012 | $-3,199,000 | $-3,199,000 |
| 2011 | $-6,980,000 | $-6,980,000 |
| 2010 | $-13,658,000 | $-13,658,000 |
| 2009 | $-14,626,000 | $-14,626,000 |
| 2008 | $-9,852,000 | $-9,852,000 |
| 2007 | $-8,918,000 | $-8,918,000 |
| 2006 | $-6,042,000 | $-6,042,000 |
| 2005 | $-6,129,000 | $-6,129,000 |